Company profile
Ticker
MGX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
832735153
MGX stock data
Latest filings (excl ownership)
8-K
Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results
14 May 24
10-Q
2024 Q1
Quarterly report
14 May 24
8-K
Nasdaq listed (MGX) Business Update Call May 1st, 2024, 5pm ET Unlocking 4 Billion Years of Microbial Evolution to Create Curative Genetic Medicines
1 May 24
8-K
Metagenomi Reports Business Updates and Full Year 2023 Financial Results
27 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
13 Feb 24
424B4
Prospectus supplement with pricing info
12 Feb 24
S-8
Registration of securities for employees
9 Feb 24
EFFECT
Notice of effectiveness
9 Feb 24
CERT
Certification of approval for exchange listing
8 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 23 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 107.81 mm | 107.81 mm | ||||
Cash burn (monthly) | 9.68 mm | 9.95 mm | ||||
Cash used (since last report) | 15.03 mm | 15.45 mm | ||||
Cash remaining | 92.78 mm | 92.35 mm | ||||
Runway (months of cash) | 9.6 | 9.3 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Brian C. Thomas | Common Stock | Grant | Acquire A | No | No | 0 | 118,992 | 0.00 | 2,496,276 |
1 Apr 24 | Brian C. Thomas | Stock Option Common Stock | Grant | Acquire A | No | No | 10.82 | 500,323 | 5.41 mm | 500,323 |
1 Apr 24 | Willard H Dere | Stock Option Common Stock | Grant | Acquire A | No | No | 10.82 | 78,636 | 850.84 k | 78,636 |
1 Apr 24 | Simren Delaney | Common Stock | Grant | Acquire A | No | No | 0 | 6,931 | 0.00 | 93,892 |
1 Apr 24 | Simren Delaney | Stock Option Common Stock | Grant | Acquire A | No | No | 10.82 | 29,145 | 315.35 k | 29,145 |
1 Apr 24 | Sebastian Bernales | Stock Option Common Stock | Grant | Acquire A | No | No | 10.82 | 78,636 | 850.84 k | 78,636 |
1 Apr 24 | Noonberg Sarah B. | Common Stock | Grant | Acquire A | No | No | 0 | 57,763 | 0.00 | 100,374 |
1 Apr 24 | Noonberg Sarah B. | Stock Option Common Stock | Grant | Acquire A | No | No | 10.82 | 242,875 | 2.63 mm | 242,875 |
News
HC Wainwright & Co. Reiterates Buy on Metagenomi, Maintains $10 Price Target
15 May 24
Metagenomi Q1 2024 Adj EPS $(1.19) Misses $(0.78) Estimate
14 May 24
HC Wainwright & Co. Initiates Coverage On Metagenomi with Buy Rating, Announces Price Target of $10
7 May 24
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars
2 May 24
12 Health Care Stocks Moving In Thursday's Intraday Session
2 May 24